Release Date: July 11, 2025
Expiration Date: July 11, 2026
Activity Overview
This educational activity is an archive of the live presentation held on Friday, May 30, 2025.
For more information about this educational activity, the faculty, and disclosures, please click here.
Target Audience
This educational program is directed toward medical oncologists, pathologists, surgical oncologists, and other physicians involved in managing pancreatic cancer.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Assess the role of molecular profiling to identify actionable alterations in patients with advanced pancreatic ductal adenocarcinoma (PDAC)
- Analyze clinical data from key trials evaluating emerging therapeutic agents for metastatic PDAC
- Integrate recent evidence and current guidelines to develop personalized treatment plans for patients with metastatic PDAC
- Apply strategies to manage treatment-related toxicities in patients with PDAC
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login HereAccreditation/Credit Designation
Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Commercial Support
This activity is supported by an educational grant from Revolution Medicines.
Physicians’ Education Resource® is proud to partner with GI Cancers Alliance
